Tiziana Life Sciences (TLSA) has completed patient enrollment for the phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis.
The trial enrolled 48 patients in the US who will receive one of two doses of intranasal foralumab or placebo over a 12-week period, to be followed by a six-month open label extension phase, the company said.
Topline data from the trial is expected in late Q3, Tiziana added.
Price: 1.73, Change: +0.12, Percent Change: +7.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments